Search Results for 'Drug Development'

Contract Service Directory Companies

View All Buyers Guide Companies »

Contract Service Directory Categories

View All Categories »

• Breaking News | Drug Development | Industry News
  

  Exelixis Acquires GamaMabs Oncology Antibody Program

  Gains AMHR2 franchise technology including all assets pertaining to GamaMabs’ monoclonal antibody drug product murlentamab.

  Kristin Brooks 05.04.21
  

  ---

• Bio News | Breaking News | Drug Development | Drug Discovery | Facilities | Industry News | Information Technology
  

  AbCellera Breaks Ground on Global HQ in Vancouver

  380,000 square feet of facilities envisioned as creative tech hub expected to be completed in 2023 and 2024.

  Tim Wright, Editor, Contract Pharma 05.03.21
  

  ---

• Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
  

  CCRM and Amgen Partner to Advance Emerging Medical Innovations

  New fund to support regenerative medicine discoveries with high potential impact for patients.

  Tim Wright, Editor, Contract Pharma 05.03.21
  

  ---

• Analytical Services | Bioanalytical Services | Breaking News | cGMP Manufacture | Drug Development | Industry News | R&D
  

  AMRI Adds R&D and Mfg. Solutions for Orphan Products

  Targeted investments globally expand scale and compound handling capabilities at facilities in Albany, Grafton, and Glasgow.

  Kristin Brooks 04.30.21
  

  ---

• Breaking News | Clinical Trials | Drug Development | Industry News
  

  Pfizer Acquires Amplyx Pharmaceuticals

  Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001).

  Tim Wright, Editor, Contract Pharma 04.29.21
  

  ---

• Breaking News | Drug Development
  

  Silo Pharma Enters Joint Venture with Zylo Therapeutics

  Will explore the clinical development of ketamine and psilocybin using ZTI’s Z-pod technology.

  Charles Sternberg, Assistant Editor 04.28.21
  

  ---

• Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Laboratory Testing
  

  Syngene, BMS Extend Long Term Research Alliance until 2030

  Extension will include a 40% increase in the number of scientists and the addition of a new 50,000 sq.-ft. dedicated lab space.

  Kristin Brooks 04.28.21
  

  ---

• Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development
  

  AavantiBio, Catalent Enter Gene Therapy Alliance

  Aims to advance AavantiBio’s gene therapy pipeline, including its lead program in Friedreich’s Ataxia (FA)

  Kristin Brooks 04.28.21
  

  ---

• Breaking News | Collaborations & Alliances | Drug Development | Formulation Development
  

  Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

  To explore synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms.

  Kristin Brooks 04.22.21
  

  ---

• Breaking News | Drug Development | Drug Discovery
  

  KemPharm Receives $10M Milestone for FDA Approval of Azstarys

  Is eligible to receive an additional near-term $10 million milestone payment following DEA scheduling of SDX.

  Charles Sternberg, Assistant Editor 04.22.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
  

  Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

  Looks to secure a supply agreement for the only inactivated vaccine candidate in clinical trials against COVID-19 in EU.

  Kristin Brooks 04.22.21
  

  ---

• Drug Development
  

  Lessons Learned: Choosing and Managing a CDMO

  This webinar on May 25 covers how putting the right parameters in place at the beginning of a client-CDMO relationship reduces risk and improves communications.

  04.21.21
  

  ---

• Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
  

  AGC Biologics Expands Partnership with Rocket Pharmaceuticals

  AGG will bolster supply across Rocket’s lentiviral vector (LVV) pipeline, with the manufacture of LVV.

  Tim Wright, Editor, Contract Pharma 04.21.21
  

  ---

• Breaking News | Drug Development | Industry News
  

  Evotec Enters Master Service Agreement with Kazia Therapeutics

  Will work together to make EVT801 available to patients globally.

  Charles Sternberg, Assistant Editor 04.19.21
  

  ---

• Breaking News | Drug Development | Industry News
  

  Bristol Myers Squibb Expands at Cambridge Crossing

  Adds remaining 113,000 square feet to its initial lease at 250 Water Street.

  Kristin Brooks 04.16.21
  

  ---

• Breaking News | Drug Development | Industry News
  

  Amgen Completes Five Prime Acquisition

  Gains pipeline of immuno-oncology and targeted cancer therapies, including a Phase 3 trial-ready, first-in-class program for gastric cancer.

  Kristin Brooks 04.16.21
  

  ---

• Breaking News | Drug Development | Industry News
  

  BioVersys Gets EIB Funds to Address Antimicrobial Resistance

  Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumannii

  Kristin Brooks 04.14.21
  

  ---

• APIs | Drug Development | Process Validation
  

  Exploring ICP-MS expertise at Almac

  A discussion about Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and its importance within drug development.

  ---

• Breaking News | Clinical Trials | Drug Development | Trials & Filings
  

  FDA Accepts Airway Therapeutics’ IND for COVID Treatment

  To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.

  Kristin Brooks 04.12.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
  

  Sanofi Acquires Tidal Therapeutics

  Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.

  Kristin Brooks 04.12.21
  

  ---

• Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
  

  Ascendia Pharmaceuticals Poised for Expansion

  CDMO secures growth equity investment from Signet Healthcare Partners.

  Tim Wright, Editor, Contract Pharma 04.09.21
  

  ---

• Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News
  

  Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

  Work together to develop and commercialize CHI’s novel dry-powder inhaler product.

  Charles Sternberg, Assistant Editor 04.07.21
  

  ---

• Breaking News | Clinical Trials | Drug Development | Industry News
  

  Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

  To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.

  Kristin Brooks 04.06.21
  

  ---

• Breaking News | Clinical Trials | CRO News | Drug Development
  

  Moleculin Selects IQVIA Biotech to Advance COVID Treatment

  IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

  Kristin Brooks 04.06.21
  

  ---

• Clinical Trials | Drug Development | QA/QC
  

  RBQM Comes of Age: COVID as a Catalyst for Change

  Clinical trial conduct has undergone a fundamental shift over the last year – and things will never be the same again.

  Online Exclusives Kristin Brooks, Managing Editor 04.01.21
  

  ---

• Breaking News | Drug Development
  

  Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

  Expands its oncology leadership capabilities in the U.S.

  Charles Sternberg, Assistant Editor 04.01.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
  

  Eloxx Pharmaceuticals Acquires Zikani Therapeutics

  Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.

  Kristin Brooks 04.01.21
  

  ---

• Clinical Trial Materials | Drug Development | Formulation Development
  

  On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture

  Watch this on-demand webinar to gain a deeper understanding of the value of adaptive processes at this critical early stage of drug development.

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
  

  Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

  Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.

  Kristin Brooks 03.30.21
  

  ---

• Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
  

  Chime Biologics Expands CDMO Capabilities

  Completes $190 million financing round to accelerate capacity expansion.

  Tim Wright, Editor, Contract Pharma 03.29.21
  

  ---

• cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
  

  Fast Track Automation in Pharmaceutical Manufacturing

  Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and risk

  Steve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
  

  CyanVac and Exothera Enter COVID-19 Vaccine Partnership

  CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.

  Tim Wright, Editor, Contract Pharma 03.25.21
  

  ---

• Drug Development
  

  Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise

  In this webinar on April 21, learn how the technologies of the OneXpress™ Solution can help streamline development and manufacturing and more.

  03.25.21
  

  ---

• Breaking News | Drug Development | Facilities | Industry News | Parenterals
  

  Eisai Begins Construction of New Injection/Research Building

  To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.

  Kristin Brooks 03.22.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
  

  Evotec, Takeda Enter Multi-RNA Target Alliance

  To discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

  Kristin Brooks 03.22.21
  

  ---

• Clinical Trials | Drug Development
  

  Regulatory Practices in a Post-Pandemic World

  Envisioning the new normal for clinical development.

  Dr. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA 03.22.21
  

  ---

• Breaking News | Clinical Trials | Drug Development | Trials & Filings
  

  Gilead, Novo Nordisk Expand NASH Alliance

  Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.

  Kristin Brooks 03.18.21
  

  ---

• Breaking News | Clinical Trials | Drug Development | Trials & Filings
  

  Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

  Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.

  Kristin Brooks 03.16.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
  

  Selexis, Pandion Enter Antibody Service Agreement

  Pandion will leverage Selexis’ SUREtechnology Platform to advance an antibody targeting autoimmune and inflammatory diseases.

  Kristin Brooks 03.16.21
  

  ---

• APIs | Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
  

  PhaseBio and BioVectra Enter into Supply Agreement

  To support development and commercialization of bentracimab.

  Tim Wright 03.11.21
  

  ---

• Breaking News | Collaborations & Alliances | Drug Development
  

  Selexis SA and BITT Enter Service Agreement

  Will develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 oncology candidate.

  Charles Sternberg, Assistant Editor 03.10.21
  

  ---

• Breaking News | cGMP Manufacture | Drug Development | Industry News
  

  Vetter Establishes Office in China

  Additional office in Asia Pacific region to promote development of new business in China.

  Kristin Brooks 03.08.21
  

  ---

• Bio News | Breaking News | Collaborations & Alliances | CRO News | Drug Development | Drug Discovery | Industry News | R&D
  

  Innoforce and dMed Enter Development Collaboration

  Aims to accelerate the development of innovative therapeutics.

  Tim Wright, Editor, Contract Pharma 03.03.21
  

  ---

• Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
  

  Pfizer Partners with Medicines Manufacturing Innovation Center

  To transform the formulation of oral solid dosage medicines.

  Tim Wright, Editor, Contract Pharma 02.25.21
  

  ---

• Breaking News | Drug Development | Industry News
  

  Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

  Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.

  Kristin Brooks 02.24.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
  

  Pfizer Selects Seven Bridges to Support RNA Sequencing Data

  Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.

  Kristin Brooks 02.24.21
  

  ---

• Breaking News | Drug Development | Promotions & Moves
  

  Aevitas Therapeutics Appoints President and CEO

  Dr. Markus Peters offers a 25-year track record of developing and commercializing orphan and specialty pharmaceuticals.

  Charles Sternberg, Assistant Editor 02.22.21
  

  ---

• Drug Development
  

  Embedding Your Drug Strategy Within a Solid Foundation for Success

  This whitepaper looks at the broad set of trends influencing pharmaceutical development and manufacturing strategy today.

  ---

• Breaking News | Collaborations & Alliances | Drug Development
  

  Lilly, Rigel Enter Exclusive CNS Development Collaboration

  Lilly will pay $125 million upfront and up to $835 million in potential milestones for Rigel's lead RIPK1 inhibitor, R552.

  Kristin Brooks 02.18.21
  

  ---

• Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
  

  Biomunex, Onward Ink Strategic Antibody Development Pact

  Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.

  Kristin Brooks 02.16.21
  

  ---